Table of Contents Author Guidelines Submit a Manuscript

Drug Development in Animal Health

Call for Papers

Besides our human fellows, we live in a world surrounded by animals, on which we rely more than we usually realize. For instance, pets give us company and affection, wild animals take care of the delicate food-chain balance, and livestock provide us with invaluable commodities such as food, leather, and wool. Likewise, our health is connected to their health and the environment, where 6 out of every 10 infectious diseases in human beings spread from animals. Despite the central importance of animal health in terms of public health and economic policy-making, many veterinary diseases still do not have an effective treatment or cure, and enough scientific reviews on this subject are not available. In addition, the zoonosis may even aggravate the situation in a global world mainly for those diseases without an effective treatment or cure, although, in such complicated scenario, specific reviews related to veterinary diseases are missing.

Similar to the human pharmaceutical industry, innovation is essential to the existence of mainline animal health companies. It may take 15 years and, perhaps, more than US$100 million to advance an animal health drug from initial concept to market. Veterinary drugs are important in maintaining the health and productivity of agricultural animals and the health of companion animals. Despite the large number of animals treated with veterinary pharmaceuticals, the human healthcare market is about 35 times larger than the combined market for all nonhuman species, which had a value in 2001 of ~US$11 billion. This market is dominated by a large number of products that generate small revenues, and so the balance between the levels of R&D investment required relative to the likely return on this investment is a particularly crucial issue in veterinary drug development. Also the scientific bibliography in this field is limited. We take one of the most important diseases in dogs, like canine arthritis, as an example. There are only around one thousand publications in the last 5 years related to “canine arthritis drug.” We did the same with the analog disease in humans and we found seventy thousand publications in the last 5 years. If we look at the tick infection drug development, one of the most important problems in livestock, we found only one thousand publications in the last 5 years.

The aim of this special issue is to concentrate the bibliographic data related to the drug development in animal health for pets and livestock, including all the development process, from the early discovery through clinical trials. This special issue invites researchers to submit innovative research studies and comprehensive review articles.

Potential topics include but are not limited to the following:

  • Enzyme inhibition
  • Drug discovery
  • Drug rational design
  • Acaricidal activity
  • Antiparasitic activity
  • Antiviral activity
  • Antibacterial activity
  • Clinical studies

Authors can submit their manuscripts through the Manuscript Tracking System at https://mts.hindawi.com/submit/journals/bmri/pharmaceutics/ddah/.

Submission DeadlineFriday, 20 April 2018
Publication DateSeptember 2018

Papers are published upon acceptance, regardless of the Special Issue publication date.

Lead Guest Editor

Guest Editors